Goodwin Guides AMAG's $700M Buy Of Stem Cell Bank
AMAG Pharmaceuticals Inc. said Monday that it will buy stem cell preservation company Cord Blood Registry from its private equity parent GTCR for $700 million with guidance from Goodwin Procter LLP....To view the full article, register now.
Already a subscriber? Click here to view full article